Compare Stocks: ABBV, AZN, LLY, and NVO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$256.27 -1.5%	$254.66	$190.75 ▼ $267.47	$452.78B	0.29	6.69 million shs	4.73 million shs
AZN Astrazeneca	$162.62 -1.3%	$169.21	$145.79 ▼ $212.71	$252.21B	0.25	2.78 million shs	3.07 million shs
LLY Eli Lilly and Company	$1,147.06 -1.1%	$1,191.71	$712.05 ▼ $1,292.65	$1.08T	0.5	3.07 million shs	2.22 million shs
NVO Novo Nordisk A/S	$46.59 -1.9%	$47.93	$35.12 ▼ $64.16	$208.02B	0.74	17.36 million shs	6.21 million shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	-0.31%	+0.95%	+6.91%	+14.50%	+23.21%
AZN Astrazeneca	+1.79%	+0.10%	+5.68%	-11.51%	+0.26%
LLY Eli Lilly and Company	+0.04%	-1.19%	+4.06%	+2.46%	+57.69%
NVO Novo Nordisk A/S	+1.38%	+2.56%	+7.45%	+10.54%	-16.39%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$256.27 -1.5%	$254.66	$190.75 ▼ $267.47	$452.78B	0.29	6.69 million shs	4.73 million shs
AZN Astrazeneca	$162.62 -1.3%	$169.21	$145.79 ▼ $212.71	$252.21B	0.25	2.78 million shs	3.07 million shs
LLY Eli Lilly and Company	$1,147.06 -1.1%	$1,191.71	$712.05 ▼ $1,292.65	$1.08T	0.5	3.07 million shs	2.22 million shs
NVO Novo Nordisk A/S	$46.59 -1.9%	$47.93	$35.12 ▼ $64.16	$208.02B	0.74	17.36 million shs	6.21 million shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	-0.31%	+0.95%	+6.91%	+14.50%	+23.21%
AZN Astrazeneca	+1.79%	+0.10%	+5.68%	-11.51%	+0.26%
LLY Eli Lilly and Company	+0.04%	-1.19%	+4.06%	+2.46%	+57.69%
NVO Novo Nordisk A/S	+1.38%	+2.56%	+7.45%	+10.54%	-16.39%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.88	Moderate Buy	$275.95	7.68% Upside
AZN Astrazeneca	2.75	Moderate Buy	$206.67	27.09% Upside
LLY Eli Lilly and Company	2.83	Moderate Buy	$1,292.18	12.65% Upside
NVO Novo Nordisk A/S	2.16	Hold	$64.94	39.38% Upside

Current Analyst Ratings Breakdown

Latest ABBV, AZN, LLY, and NVO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/1/2026	LLY Eli Lilly and Company	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Outperform ➝ Buy
8/27/2026	NVO Novo Nordisk A/S	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Sell
8/26/2026	LLY Eli Lilly and Company	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
8/23/2026	AZN Astrazeneca	CICC Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$198.00
8/20/2026	ABBV AbbVie	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$298.00 ➝ $303.00
8/17/2026	ABBV AbbVie	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$295.00 ➝ $300.00
8/13/2026	ABBV AbbVie	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$300.00
8/12/2026	NVO Novo Nordisk A/S	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$47.00
8/12/2026	NVO Novo Nordisk A/S	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
8/11/2026	LLY Eli Lilly and Company	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
8/11/2026	ABBV AbbVie	BNP Paribas Exane Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$218.00 ➝ $247.00

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$64.39B	7.03	$14.83 per share	17.28	($3.33) per share	-76.96
AZN Astrazeneca	$58.74B	4.29	$13.01 per share	12.50	$32.48 per share	5.01
LLY Eli Lilly and Company	$65.18B	16.57	$24.86 per share	46.15	$35.99 per share	31.87
NVO Novo Nordisk A/S	$46.80B	4.45	$4.67 per share	9.98	$6.58 per share	7.08

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.23B	$3.54	72.39	15.87	1.18	9.80%	-422.07%	14.34%	10/30/2026 (Estimated)
AZN Astrazeneca	$10.23B	$6.69	24.31	14.34	1.26	17.02%	31.45%	13.20%	10/30/2026 (Estimated)
LLY Eli Lilly and Company	$20.64B	$29.80	38.49	25.01	1.44	33.53%	97.83%	23.23%	10/29/2026 (Estimated)
NVO Novo Nordisk A/S	$15.51B	$4.09	11.39	13.62	1.57	35.36%	61.20%	21.49%	11/4/2026 (Estimated)

Latest ABBV, AZN, LLY, and NVO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2026	Q2 2026	LLY Eli Lilly and Company	$6.40	$8.38	+$1.98	$7.94	$20.82 billion	$22.97 billion
8/5/2026	Q2 2026	NVO Novo Nordisk A/S	$0.77	$0.96	+$0.19	$0.72	$10.89 billion	$11.98 billion
7/31/2026	Q2 2026	ABBV AbbVie	$3.61	$3.65	+$0.04	$2.03	$16.80 billion	$16.99 billion
7/27/2026	Q2 2026	AZN Astrazeneca	$2.50	$2.63	+$0.13	$0.8050	$15.44 billion	$15.38 billion
6/30/2026	Q2 2026	NVO Novo Nordisk A/S	N/A	$0.9440	N/A	$0.72	N/A	$11.98 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.92	2.70%	+6.80%	195.48%	53 Years
AZN Astrazeneca	$4.34	2.67%	+2.30%	64.87%	N/A
LLY Eli Lilly and Company	$6.92	0.60%	+15.18%	23.22%	11 Years
NVO Novo Nordisk A/S	$0.82	1.76%	+21.74%	20.05%	N/A

Latest ABBV, AZN, LLY, and NVO Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/22/2026	LLY Eli Lilly and Company	quarterly	$1.73	0.59%	8/14/2026	8/14/2026	9/10/2026
8/5/2026	NVO Novo Nordisk A/S		$0.5786	2.58%	8/17/2026	8/17/2026	8/25/2026
6/18/2026	ABBV AbbVie	quarterly	$1.73	2.83%	7/15/2026	7/15/2026	8/14/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	N/A	0.81	0.69
AZN Astrazeneca	0.47	0.89	0.67
LLY Eli Lilly and Company	1.41	1.35	1.00
NVO Novo Nordisk A/S	0.59	0.79	0.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
AZN Astrazeneca	20.35%
LLY Eli Lilly and Company	82.53%
NVO Novo Nordisk A/S	11.54%

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.06%
AZN Astrazeneca	N/A
LLY Eli Lilly and Company	0.14%
NVO Novo Nordisk A/S	0.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	57,000	1.77 billion	1.77 billion	Optionable
AZN Astrazeneca	96,100	1.55 billion	N/A	N/A
LLY Eli Lilly and Company	50,000	941.36 million	940.04 million	Optionable
NVO Novo Nordisk A/S	69,505	4.47 billion	4.46 billion	Optionable

ABBV, AZN, LLY, and NVO Headlines

Recent News About These Companies

Novo Nordisk (CPSE:NOVO B) Stock Looks Below Fair Value But Faces Earnings Doubts

1 hour ago | finance.yahoo.com

Novo Nordisk's Oral Wegovy Bets on German Pharmacy Shelves to Reset a Bruised Narrative

September 4 at 1:26 PM | ad-hoc-news.deA

Novo Nordisk Falls 2% as Wegovy Opens a German Front

September 4 at 1:26 PM | finance.yahoo.com

Novo Nordisk's China Filing Sets Up a London Showdown Investors Are Watching Closely

September 4 at 1:03 AM | ad-hoc-news.deA

Wegovy’s German Debut Opens a New Front for Novo Nordisk (NVO)

September 2 at 11:31 PM | insidermonkey.com

Citi flags GLP-1 prescription slowdown at Novo Nordisk, reiterates 'sell'

September 2 at 2:29 PM | proactiveinvestors.com

European Equities Traded in the US as American Depositary Receipts Track Higher in Wednesday Trading

September 2 at 2:29 PM | finance.yahoo.com

Citi flags GLP-1 prescription slowdown at Novo Nordisk, reiterates 'sell'

September 2 at 10:35 AM | proactiveinvestors.co.uk

Novo Nordisk A/S : Deutsche Bank reiterates its Sell rating

September 2 at 9:29 AM | marketscreener.comM

Novo Nordisk (CPSE:NOVO B), What Is Behind The Fresh Attention?

September 1 at 7:45 PM | finance.yahoo.com

Novo Nordisk Trades Nearly 58% Below GF Value as Wegovy Pill Launches in Germany

September 1 at 2:44 PM | finance.yahoo.com

A leadership gap looms in Nordic and Benelux boardrooms

September 1 at 9:23 AM | finance.yahoo.com

Novo Nordisk launches Wegovy weight-loss pill in Germany

September 1 at 4:55 AM | reuters.com

GLP-1 weight loss drugs effective even at low starter doses

August 31, 2026 | reuters.com

Novo Nordisk's Balancing Act: A Chinese Filing, a Failed Trial, and a Buyback That Speaks Volumes

August 31, 2026 | ad-hoc-news.deA

GLP-1 obesity drugs: A market that's getting more crowded

August 31, 2026 | seekingalpha.com

Can CagriSema Help Novo Nordisk Close the Gap With LLY in Obesity?

August 31, 2026 | finance.yahoo.com

Can CagriSema Help Novo Nordisk Close the Gap With LLY in Obesity?

August 31, 2026 | zacks.com

Novo Nordisk A/S - share repurchase programme

August 31, 2026 | finance.yahoo.com

Novo Nordisk: Why The Price Remains Stubbornly Low (Rating Downgrade)

August 31, 2026 | seekingalpha.com

Novo Nordisk A/S (NYSE:NVO) Receives Consensus Rating of "Hold" from Analysts

August 31, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ABBV, AZN, LLY, and NVO Company Descriptions

AbbVie NYSE:ABBV

$256.27 -3.94 (-1.51%)

As of 03:58 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Astrazeneca NYSE:AZN

$162.62 -2.15 (-1.30%)

As of 03:58 PM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Eli Lilly and Company NYSE:LLY

$1,147.06 -12.54 (-1.08%)

As of 03:58 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S NYSE:NVO

$46.59 -0.92 (-1.94%)

As of 03:58 PM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABBV, AZN, LLY, and NVO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABBV, AZN, LLY, and NVO Earnings

Compare Dividends

Latest ABBV, AZN, LLY, and NVO Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABBV, AZN, LLY, and NVO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ABBV, AZN, LLY, and NVO Company Descriptions

AbbVie NYSE:ABBV

Astrazeneca NYSE:AZN

Eli Lilly and Company NYSE:LLY

Novo Nordisk A/S NYSE:NVO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools